publication venue for
- Abstract PO081: Systematic Generation of Allogeneic Immune-targeting Modalities for Glioblastoma 2021
- Abstract PR009: The functional genomic landscape of recurrent glioblastoma 2021
- Systematic Generation of Allogeneic Immune-targeting Modalities for Glioblastoma. 2021
- The functional genomic landscape of recurrent glioblastoma. 2021
- The functional genomic landscape of recurrent glioblastoma. 2021
- Abstract B207: Nivolumab +/- Ipilimumab in patients with hypermutated cancers detected in blood: NIMBLE 2019
- Abstract B079: The efficacy of CD133 BiTEs and CAR-T cells in preclinical model of recurrent glioblastoma 2016
- Abstract B092: Therapeutic targeting of tumorigenic EphA2+/EphA3+ brain tumor initiating cells with bi-specific antibody in glioblastoma 2016
- Abstract B077: Evaluating oncolytic vaccines targeting mutated epitopes in a murine fibrosarcoma model CMS-5 2016
- Abstract B096: Oncolytic vaccination for HPV induced cancer 2016
- Level of expression of MHCI-presented neoepitopes influences tumor rejection by neoantigen-specific CD8+ T cells. 2024
- Determinants for Antitumor and Protumor Effects of Programmed Cell Death. 12:7-16. 2024
- Deciphering the Immunomodulatory Capacity of Oncolytic Vaccinia Virus to Enhance the Immune Response to Breast Cancer. 8:618-631. 2020
- TGFβ Programs Central Memory Differentiation inEx Vivo–Stimulated Human T Cells. 7:1426-1439. 2019
- Expanded CD56superbrightCD16+ NK Cells from Ovarian Cancer Patients Are Cytotoxic against Autologous Tumor in a Patient-Derived Xenograft Murine Model. 6:1174-1185. 2018
- The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma. 6:758-765. 2018
- Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events. 6:402-408. 2018
- Customized Viral Immunotherapy for HPV-Associated Cancer. 5:847-859. 2017
- Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer. 4:881-892. 2016
- Cell-free Tumor Microparticle Vaccines Stimulate Dendritic Cells via cGAS/STING Signaling. 3:196-205. 2015
- Combining Oncolytic HSV-1 with Immunogenic Cell Death-Inducing Drug Mitoxantrone Breaks Cancer Immune Tolerance and Improves Therapeutic Efficacy. 1:309-319. 2013